JDQ-443 (Synonyms: NVP-JDQ443) |
Katalog-Nr.GC63564 |
JDQ-443 ist ein oral aktiver, potenter, selektiver und kovalenter KRAS G12C-Inhibitor (aus dem Patent WO2021120890A1 entnommen). JDQ-443 zeigt AntitumoraktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2653994-08-0
Sample solution is provided at 25 µL, 10mM.
JDQ-443 (example 1a) is a covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1)[1].
JDQ-443 (NVP-JDQ443) traps the GDP-bound inactive conformation of KRAS[1].
[1]. LIU BO, et al. PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS. Patent WO2021120890A1.
Average Rating: 5
(Based on Reviews and 19 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *